Petra Pharma
Pioneering novel therapies to address cancer and metabolic disorders by targeting essential cellular processes, established in 2016 and based in New York.
Pioneering novel therapies to address cancer and metabolic disorders by targeting essential cellular processes, established in 2016 and based in New York.
Petra Pharma is a clinical-stage pharmaceutical company dedicated to developing novel therapies for serious medical conditions such as cancer and metabolic diseases. Founded in 2016 and based in New York, USA, Petra Pharma focuses on targeting essential cellular processes, including cell division, growth, trafficking, and signaling, through unique enzyme targets. The company's innovative approach involves the development of small molecules aimed at addressing these cellular processes to have a therapeutic impact on human health. Petra Pharma recently secured a $27.55M Debt Financing investment on 15 April 2020. With its pioneering efforts and strategic focus, Petra Pharma presents a compelling opportunity for potential venture capital interest.
| Funding Stage | Amount | No. Investors | Investors | Date |
|---|---|---|---|---|
| Debt Financing | $27.55M | - | 15 Apr 2020 | |
| Series A | $48.00M | 10 |
|
06 Jan 2016 |
No recent news or press coverage available for Petra Pharma.
We care about your data, and we'd love to use cookies make your experience better.
